Vildagliptin Compared to Pioglitazone in Combination With Metformin in Patients With Type 2 Diabetes
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Many people with type 2 diabetes cannot maintain target blood glucose levels when taking a
single oral drug. The purpose of this study is to assess the long-term safety and
effectiveness of vildagliptin, an unapproved drug, compared to that of pioglitazone in
lowering overall blood glucose levels when added to metformin in people with type 2 diabetes
not at target blood glucose levels on metformin alone.